Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Operating Expenses (2022 - 2025)

Historic Operating Expenses for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $48.7 million.

  • Entrada Therapeutics' Operating Expenses rose 1803.87% to $48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $183.1 million, marking a year-over-year increase of 1627.7%. This contributed to the annual value of $163.8 million for FY2024, which is 2390.47% up from last year.
  • Entrada Therapeutics' Operating Expenses amounted to $48.7 million in Q3 2025, which was up 1803.87% from $48.8 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Operating Expenses ranged from a high of $48.8 million in Q2 2025 and a low of $22.2 million during Q1 2022
  • Its 4-year average for Operating Expenses is $35.5 million, with a median of $36.9 million in 2023.
  • As far as peak fluctuations go, Entrada Therapeutics' Operating Expenses skyrocketed by 4616.66% in 2023, and later surged by 1142.16% in 2025.
  • Over the past 4 years, Entrada Therapeutics' Operating Expenses (Quarter) stood at $25.6 million in 2022, then skyrocketed by 44.43% to $36.9 million in 2023, then rose by 17.11% to $43.3 million in 2024, then increased by 12.48% to $48.7 million in 2025.
  • Its last three reported values are $48.7 million in Q3 2025, $48.8 million for Q2 2025, and $42.3 million during Q1 2025.